• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Intarcia Therapeutics, Inc. - Product Pipeline Review - Q4 2010 Product Image

Intarcia Therapeutics, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1446248
  • November 2010
  • 50 pages
  • GlobalData

Intarcia Therapeutics, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Intarcia Therapeutics, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Intarcia Therapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Intarcia Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Intarcia Therapeutics, Inc. Snapshot
Intarcia Therapeutics, Inc. Overview
Key Information
Key Facts
Intarcia Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Intarcia Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Intarcia Therapeutics, Inc. – Pipeline Products Glance
Intarcia Therapeutics, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Intarcia Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Intarcia Therapeutics, Inc.–Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Intarcia Therapeutics, Inc. – Drug Profiles
Atamestane + Toremifene
Product Description
Mechanism of Action
R&D Progress
ITCA 650
Product Description
Mechanism of Action
R&D Progress
Biomed 101
Product Description
Mechanism of Action
R&D Progress
ITCA 638
Product Description
Mechanism of Action
R&D Progress
ITCA 638 + Ribavirin
Product Description
Mechanism of Action
R&D Progress
ITCA 880
Product Description
Mechanism of Action
R&D Progress
ITCA 884
Product Description
Mechanism of Action
R&D Progress
Intarcia Therapeutics, Inc. – Pipeline Analysis
Intarcia Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Intarcia Therapeutics, Inc. Pipeline Products By Target
Intarcia Therapeutics, Inc. – Pipeline Products by Route of Administration
Intarcia Therapeutics, Inc. – Pipeline Products by Molecule Type
Intarcia Therapeutics, Inc. – Recent Pipeline Updates
Intarcia Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Sep 22, 2010: Intarcia Presents Positive ITCA 650 Phase II Study Results For Type 2 Diabetes At EASD
Jun 28, 2010: Intarcia Presents Positive ITCA 650 Phase II Study Results At American Diabetes Association 70th Scientific Sessions
Nov 06, 2009: Intarcia Therapeutics, Inc. Presents Positive Results From Two Studies Of ITCA 650 For The Treatment Of Type 2 Diabetes At The Ninth Annual Diabetes Technology Meeting.
Sep 30, 2009: Intarcia Therapeutics, Inc. Presents Positive Results Of ITCA 650 Phase 1b Study In Type 2 Diabetes At The European Association For The Study Of Diabetes Conference
Sep 17, 2009: Intarcia Therapeutics, Inc. Commences Enrollment Of ITCA 650 Phase 2 Study In Type 2 Diabetes
May 27, 2009: Intarcia Therapeutics, Inc. Announces Acceptance Of ITCA 650 Phase 1b Study For Late-Breaker Presentation At The American Diabetes Association 69th Scientific Sessions
Apr 24, 2009: Intarcia Therapeutics, Inc. Announces Completion Of Enrollment Of ITCA 650 Phase 1b Study For The Treatment Of Type 2 Diabetes
Feb 25, 2005: INTARCIA THERAPEUTICS ANNOUNCES ITS PHASE 3 CLINICAL TRIAL FOR ADVANCED BREAST CANCER DRUG, ATAMESTANE
Aug 08, 2002: BioMedicines Initiates World-Wide Phase 3 Breast Cancer Clinical Program
Aug 07, 2002: BioMedicines, Inc. Completes Phase Ib Enrollment With Biomed 101
Financial Deals Landscape
Intarcia Therapeutics, Inc., Deals Volume Summary, 2004 to YTD 2010
Intarcia Therapeutics, Inc., Deals Summary By Region, 2004 to YTD 2010
Intarcia Therapeutics, Inc., Deals Summary, 2004 to YTD 2010
Intarcia Therapeutics, Inc. Detailed Deal Summary
Venture Financing
Intarcia Therapeutics Secures $50 Million In Series B Financing
Intarcia Therapeutics Secures $50 Million In Series E Financing
BioMedicines Secures $38 Million In Financing
Equity Offering
Intarcia Therapeutics Withdraws Initial Public Offering
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS